CompletedPhase 3Phase 4ACTRN12605000308695

Perioperative ischaemic evaluation trial

The effect of perioperative metoprolol on cardiac morbidity and mortality in patients presenting for non-cardiac surgery

Sponsor

MediClin Pty Ltd

Enrollment

10,000 participants

Start Date

Jan 31, 2003

Study Type

Interventional

Conditions

Perioperative cardiac morbidity and mortality within 30 days of surgery

Summary

Patients with or at risk of ischaemic heart disease, who are having moderate or high risk non-cardiac surgery will be randomized to receive metoprolol CR or placebo for 30 days perioperatively. Outcomes include cardiac morbidity and mortality and safety endpoints.

Eligibility

Sex: Both males and femalesMin Age: 45 Yearss

Plain Language Summary

Simplified for easier understanding

This study is about perioperative ischaemic evaluation trial. It may be open to people who are at least 45 years old. Participants generally need to have with or at risk of ischaemic heart disease. having moderatie or high risk non-cardiac surgery.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Metoprolol CR 200 mg daily for 30 days.

Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000308695